Your browser doesn't support javascript.
loading
Adverse drug events caused by three high-risk drug-drug interactions in patients admitted to intensive care units: A multicentre retrospective observational study.
Klopotowska, Joanna E; Leopold, Jan-Hendrik; Bakker, Tinka; Yasrebi-de Kom, Izak; Engelaer, Frouke M; de Jonge, Evert; Haspels-Hogervorst, Esther K; van den Bergh, Walter M; Renes, Maurits H; Jong, Bas T de; Kieft, Hans; Wieringa, Andre; Hendriks, Stefaan; Lau, Cedric; van Bree, Sjoerd H W; Lammers, Hendrick J W; Wierenga, Peter C; Bosman, Rob J; de Jong, Vincent M; Slijkhuis, Mirjam; Franssen, Eric J F; Vermeijden, Wytze J; Masselink, Joost; Purmer, Ilse M; Bosma, Liesbeth E; Hoeksema, Martin; Wesselink, Elsbeth; de Lange, Dylan W; de Keizer, Nicolette F; Dongelmans, Dave A; Abu-Hanna, Ameen.
Affiliation
  • Klopotowska JE; Department of Medical Informatics, Amsterdam UMC location University of Amsterdam, Amsterdam, The Netherlands.
  • Leopold JH; Amsterdam Public Health, Amsterdam, The Netherlands.
  • Bakker T; Department of Medical Informatics, Amsterdam UMC location University of Amsterdam, Amsterdam, The Netherlands.
  • Yasrebi-de Kom I; Amsterdam Public Health, Amsterdam, The Netherlands.
  • Engelaer FM; Department of Medical Informatics, Amsterdam UMC location University of Amsterdam, Amsterdam, The Netherlands.
  • de Jonge E; Amsterdam Public Health, Amsterdam, The Netherlands.
  • Haspels-Hogervorst EK; Department of Medical Informatics, Amsterdam UMC location University of Amsterdam, Amsterdam, The Netherlands.
  • van den Bergh WM; Amsterdam Public Health, Amsterdam, The Netherlands.
  • Renes MH; Department of Intensive Care, Leiden University Medical Center, Leiden, The Netherlands.
  • Jong BT; Department of Intensive Care, Leiden University Medical Center, Leiden, The Netherlands.
  • Kieft H; Department of Critical Care, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
  • Wieringa A; Department of Critical Care, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
  • Hendriks S; Department of Critical Care, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
  • Lau C; Department of Intensive Care, Isala Hospital, Zwolle, The Netherlands.
  • van Bree SHW; Department of Intensive Care, Isala Hospital, Zwolle, The Netherlands.
  • Lammers HJW; Department of Clinical Pharmacy, Isala Hospital, Zwolle, The Netherlands.
  • Wierenga PC; Department of Intensive Care, Albert Schweitzer Hospital, Dordrecht, The Netherlands.
  • Bosman RJ; Department of Hospital Pharmacy, Albert Schweitzer Hospital, Dordrecht, The Netherlands.
  • de Jong VM; Department of Intensive Care, Hospital Gelderse Vallei, Ede, The Netherlands.
  • Slijkhuis M; Department of Hospital Pharmacy, Hospital Gelderse Vallei, Ede, The Netherlands.
  • Franssen EJF; Department of Hospital Pharmacy, Hospital Gelderse Vallei, Ede, The Netherlands.
  • Vermeijden WJ; Department of Intensive Care Medicine, OLVG Hospital, Amsterdam, The Netherlands.
  • Masselink J; Department of Intensive Care Medicine, OLVG Hospital, Amsterdam, The Netherlands.
  • Purmer IM; Department of Clinical Pharmacy, OLVG Hospital, Amsterdam, The Netherlands.
  • Bosma LE; Department of Clinical Pharmacy, OLVG Hospital, Amsterdam, The Netherlands.
  • Hoeksema M; Department of Intensive Care, Medisch Spectrum Twente, Enschede, The Netherlands.
  • Wesselink E; Department of Hospital Pharmacy, Medisch Spectrum Twente, Enschede, The Netherlands.
  • de Lange DW; Department of Intensive Care, Haga Hospital, The Hague, The Netherlands.
  • de Keizer NF; Department of Hospital Pharmacy, Haga Hospital, The Hague, The Netherlands.
  • Dongelmans DA; Department of Intensive Care, Zaans Medisch Centrum, Zaandam, The Netherlands.
  • Abu-Hanna A; Department of Hospital Pharmacy, Zaans Medisch Centrum, Zaandam, The Netherlands.
Br J Clin Pharmacol ; 90(1): 164-175, 2024 01.
Article in En | MEDLINE | ID: mdl-37567767
ABSTRACT

AIMS:

Knowledge about adverse drug events caused by drug-drug interactions (DDI-ADEs) is limited. We aimed to provide detailed insights about DDI-ADEs related to three frequent, high-risk potential DDIs (pDDIs) in the critical care

setting:

pDDIs with international normalized ratio increase (INR+ ) potential, pDDIs with acute kidney injury (AKI) potential, and pDDIs with QTc prolongation potential.

METHODS:

We extracted routinely collected retrospective data from electronic health records of intensive care units (ICUs) patients (≥18 years), admitted to ten hospitals in the Netherlands between January 2010 and September 2019. We used computerized triggers (e-triggers) to preselect patients with potential DDI-ADEs. Between September 2020 and October 2021, clinical experts conducted a retrospective manual patient chart review on a subset of preselected patients, and assessed causality, severity, preventability, and contribution to ICU length of stay of DDI-ADEs using internationally prevailing standards.

RESULTS:

In total 85 422 patients with ≥1 pDDI were included. Of these patients, 32 820 (38.4%) have been exposed to one of the three pDDIs. In the exposed group, 1141 (3.5%) patients were preselected using e-triggers. Of 237 patients (21%) assessed, 155 (65.4%) experienced an actual DDI-ADE; 52.9% had severity level of serious or higher, 75.5% were preventable, and 19.3% contributed to a longer ICU length of stay. The positive predictive value was the highest for DDI-INR+ e-trigger (0.76), followed by DDI-AKI e-trigger (0.57).

CONCLUSION:

The highly preventable nature and severity of DDI-ADEs, calls for action to optimize ICU patient safety. Use of e-triggers proved to be a promising preselection strategy.
Subject(s)
Key words

Full text: 1 Database: MEDLINE Main subject: Drug-Related Side Effects and Adverse Reactions / Acute Kidney Injury Type of study: Etiology_studies / Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Year: 2024 Type: Article

Full text: 1 Database: MEDLINE Main subject: Drug-Related Side Effects and Adverse Reactions / Acute Kidney Injury Type of study: Etiology_studies / Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Year: 2024 Type: Article